683 Capital Management’s ImmunityBio IBRX Stock Holding History

683 Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-58,748	Closed	-$223K	–	160
2019 Q4	$223K	Buy	+58,748	New	+$100K	0.03%	94

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

683 Capital Management's IBRX Position: Q1 2020 in Review

683 Capital Management sold out of ImmunityBio (IBRX) in Q1 2020, closing a stake of 58,748 shares — an estimated $223K sold.

683 Capital Management first reported a position in IBRX in Q4 2019 and held it in 1 quarter. The position peaked at $223K in Q4 2019. 49 funds tracked by Wall St. Rank hold IBRX as of Q1 2020.

683 Capital Management reported no remaining ImmunityBio position as of Q1 2020 after selling out during the quarter.
683 Capital Management sold 58,748 ImmunityBio shares in Q1 2020, an estimated $223K.
683 Capital Management first reported a position in ImmunityBio in Q4 2019 and held it in 1 quarter.
683 Capital Management's ImmunityBio position peaked at $223K in Q4 2019.
49 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.